Chloe Borden

Chloe Borden

Auto-generated profile, based on publicly available information

Chloe Borden

The Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2026 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
SBShwetha Bindhu
Shwetha Bindhu
ELEuyn Lim
Euyn Lim
CBChloe Borden
Chloe Borden
MGMichael George
Michael George
XTXin Yee Tan
Xin Yee Tan
XWXiangling Wang
Xiangling Wang
An abstract is unavailable. This article is available as a PDF only.

25 December 2025 in Kidney Medicine
Verified
Journal Article
Open access
CBChloe Borden
Chloe Borden
ICIman Chaudhry
Iman Chaudhry
RMRhyan Maditz
Rhyan Maditz
SMSarah Mazzola
Sarah Mazzola
RKRonit Salomon Kent
Ronit Salomon Kent
XWXiangling Wang
Xiangling Wang
Genetic testing is increasingly used to assist the precise diagnosis and clinical management of suspected genetic kidney diseases; however, mitochondrial DNA (mtDNA) analysis remains underutilized. Here we report a 61-year-old man who presented with chronic kidney disease (CKD), microscopic hematuria since childhood, bilateral sensorineural hearing loss (SNHL), and peripheral polyneuropathy. Laboratory reports showed serum creatinine 1.5 mg/dL with an estimated glomerular filtration rate of 55 mL/min/1.73m2, no proteinuria, and a negative serological workup. Kidney biopsy demonstrated focal segmental glomerulosclerosis (FSGS) with segmental thinning of glomerular basement membrane and dysmorphic mitochondria. A 401 renal disease gene panel was negative, including type IV collagen genes. mtDNA analysis identified a pathogenic variant in the MT-TV gene (m.1642 G>A; NC_012920.1) with 2% heteroplasmy in leukocyte-derived DNA, confirmed in urine-derived DNA at 5% heteroplasmy. Genetic counseling was offered along with systemic evaluation revealing left ventricular hypertrophy on echocardiogram. The patient was started on levocarnitine and coenzyme Q10 with multidisciplinary care. This is the first reported case of FSGS with dysmorphic mitochondria and a pathogenic MT-TV variant confirmed via both leukocyte-derived and urine-derived DNA. It supports the role of mitochondrial dysfunction in CKD and highlights the importance of mtDNA analysis in the evaluation of FSGS and unexplained CKD.

11 June 2025 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
CBChloe Borden
Chloe Borden
MNMuhammad Bin Nasir
Muhammad Bin Nasir
MRMary‐Beth Roberts
Mary‐Beth Roberts
LPLauren Palange
Lauren Palange
XWXiangling Wang
Xiangling Wang

23 June 2026 in Advances in Kidney Disease and Health
Verified
Journal Article
Open access
CBChloe Borden
Chloe Borden
KDKatherine M. Dell
Katherine M. Dell
Cystic kidney diseases are an important cause of pediatric morbidity and mortality. Most genetic cystic kidney diseases are "ciliopathies", a group of disorders that share a common feature of abnormal structure or function of the primary cilia. Ciliopathies represent a broad range of clinically and genetically heterogenous disorders, which affect multiple organ systems. Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are the 2 most common etiologies, affecting 1:1000-2500 and 1:20,000-40,000 individuals, respectively. Although historically referred to as "adult" (ADPKD) and "infantile" (ARPKD) polycystic kidney disease, it is now understood that age at presentation is variable. Approximately 3% of ADPKD patients present with very early onset, severe features that mimic ("phenocopy") typical ARPKD. Similarly, a minority of ARPKD cases present as late as young adulthood. Due to their heterogeneity, ADPKD, ARPKD, and other phenocopies, such as hepatocyte nuclear factor-1 beta-associated kidney disease, can be difficult to distinguish clinically, making molecular genetic testing a valuable diagnostic resource. The purpose of this review is to provide a comprehensive overview of the clinical and genetic spectrum and molecular diagnosis of cystic kidney diseases in children, with a specific focus on ADPKD and ARPKD.